The informal sector in Nigeria is one of the chief sources of drugs for retail businesses for resell to end-users. Despite the surge in informal trade in recent years, the formal sector however remains the most important channel of supply. In the past, the lack of appropriate regulations and enforcement has fuelled concerns about the quality and legitimacy of products, thus affecting all drug suppliers including formal distributors and suppliers. This is however poised to change in future with the improving regulatory environment. New analysis from Frost & Sullivan Distributor Analysis in Nigeria, finds that the pharmaceutical market in Nigeria earned revenues of $778.0 million in 2009 and estimates this to reach $2.61 billion in 2016. The following segments are covered in the research: pharmaceuticals and medical devices. "Growth in the pharmaceutical market is expected to be driven by the increasing availability of low cost generic drugs," notes Frost & Sullivan Healthcare Research Analyst Ishe Zingoni. "This positive trend will be further reinforced by an improving regulatory system." An improved regulatory system is anticipated to boost uptake of drugs by inspiring end-user confidence and eliminating competition from illegal imports and sub-standard products. The leakage of supply into the informal sector has been a key challenge for manufacturers, as quality assurance mechanisms cannot be enforced within the sector. These mechanisms include monitoring of storage conditions and product expiration - all factors that affect treatment outcomes. As the informal sector is very significant source of drugs for businesses at the retail level, it has affected customer confidence even in legitimate pharmacies and distributors. "Although it is difficult to regulate the informal sector adequately, the regulatory agency, NAFDAC, has been making considerable progress in reducing the problem of sub-standard and illegal products," remarks Zingoni. "Recent interventions which include the introduction of the Drug Distribution Inspection Committee (DDIC) will improve enforcement through regular inspection of documentation throughout the supply chain." Through vertical integration, manufacturers in Nigeria are now moving into distribution, and gaining greater control of the supply chain. The major manufacturers in the country are setting up their own distribution subsidiaries that distribute directly to retail pharmacies and patent medicine vendors (PMVs).
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment